Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Elevated homocysteine is associated with increased risk of heart disease, stroke, and dementia. Therapy of Parkinson disease (PD) with levodopa elevates homocysteine. The authors conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled trial to test whether folate 1 mg/vitamin B(12) 500 microg or entacapone reduced serum homocysteine in 35 levodopa-treated PD patients. Levodopa initiation caused a small elevation in homocysteine. Vitamin therapy, but not entacapone, resulted in a decrease in homocysteine compared to placebo.
Postuma
R B
RB
Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. ron.postuma@muhc.mcgill.ca
Espay
A J
AJ
Zadikoff
C
C
Suchowersky
O
O
Martin
W R W
WR
Lafontaine
A-L
AL
Ranawaya
R
R
Camicioli
R
R
Lang
A E
AE
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002170:Canada; D002396:Catechols / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control*; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010300:Parkinson Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy; D015990:Placebo Effect; D016896:Treatment Outcome; D014481:United States; D014805:Vitamin B 12 / Q000008:administration & dosage*; D014815:Vitamins / Q000627:therapeutic use
D000978:Antiparkinson Agents; D002396:Catechols; D004338:Drug Combinations; D009570:Nitriles; D014815:Vitamins; D006710:Homocysteine; D007980:Levodopa; C071192:entacapone; D005492:Folic Acid; D014805:Vitamin B 12